Background and Aim: The efficacy of telbivudine for breaking vertical transmission of hepatitis B virus has been well established. Data on the risk of postpartum flare after telbivudine withdrawal and efficacy of extended antiviral therapy after delivery are limited. Methods: Chronic hepatitis B virus-infected women who received telbivudine beginning at week 24 or 28 of gestation were enrolled and then followed up to 52 weeks postpartum. Virological and biochemical parameters were assessed. Results: Of the 241 women who finished 52 weeks of follow-up, 33.6% had elevated serum alanine aminotransferase (ALT) during pregnancy. Telbivudine administration resulted in ALT normalization in 85.2% before delivery. Compared with women having a normal ALT level throughout pregnancy, those with elevated ALT had a significantly higher rate of ALT flare after telbivudine withdrawal (25.0% vs 11.9%; χ 2 = 4.273, P = 0.039). Multivariate analysis indicated that only ALT elevation during pregnancy correlated with postpartum flare after telbivudine withdrawal. Those women with elevated ALT during pregnancy continued antiviral treatment to 52 weeks postpartum and had a significantly higher HBeAg seroconversion rate (P = 0.001) and a notable decrease in HBsAg titers (P = 0.001). Conclusion: It is safe for the majority of women to withdraw telbivudine after delivery, whereas exciting serological response encourages extended antiviral therapy for mother with ALT elevation during pregnancy.
Introduction
Mother-to-infant transmission is the most common mode of perpetuating chronic hepatitis B virus (HBV) infection in endemic countries. 1 In the era of universal HBV vaccination, transmission from highly viremic mothers remains a major challenge to reducing HBV infection, 2 for whom an infection rate as high as 9-20% has been displayed. [3] [4] [5] Nucleos(t)ide analog therapy is preferred for these mothers during second or third trimester. [5] [6] [7] [8] The efficacy and safety of telbivudine for preventing HBV mother-to-infant transmission have been well demonstrated. 6, 7 However, several controversies over antiviral treatment have not been resolved, that is, optimal duration, effect of postpartum therapy, and risk of postpartum alanine aminotransferase (ALT) flare after withdrawal. 9 Substantive immune-mediated and physiological changes are known to arise during fetal development; 10, 11 the adjustment of the maternal immune system to tolerate fetal antigens occurs. 12, 13 placenta, systemic immunity to HBV infection is modulated accordingly. 14, 15 In addition, the metabolic load on liver is significantly increased during pregnancy; a rate of 0.3-3% hepatic flare has been reported. 16, 17 The reactivation of HBV owing to immune adjustment can aggravate the process, even causing liver failure, among which HBV-associated mortality ranges from 43% to 80%. 18, 19 It is well accepted that antiviral treatment during pregnancy can mollify inflammation-induced liver damage. 20 After delivery, the hormone level changes rapidly, the immune system reconstructs, and the ALT shows an increase tendency. Of patients, 25-43% display active hepatitis, mainly in the first 3 months postpartum. Acute exacerbation or even fulminant hepatic failure has been reported after delivery, even with lamivudine therapy. A small cohort observation showed independence of postpartum ALT flare with antiviral therapy and viremia. 15 The recommended duration of antiviral therapy after delivery has not been thoroughly investigated. In published studies, antiviral treatment was discontinued from delivery to 3 months postpartum in most mothers; the parturients with HBeAg loss or seroconversion were recommended to continue antiviral treatment after delivery. 6, 21 Considering common ALT flare after delivery, it may be a unique opportunity for antiviral therapy for women of childbearing age, whereas there are limited results on the efficacy of extended antiviral therapy after delivery from this special population, as well as outcomes with different interventions. Lu et al. reported a high rate of viral response in chronic hepatitis B pregnant woman with normal levels of ALT who accepted treatment of combining Peg-interferon a-2a with adefovir after childbirth. 22 In this multicenter, prospective observation, chronically HBVinfected women with high viral titer, who received LdT from the second or third trimester with ALT flare or not, were enrolled and followed up for at least 52 weeks postpartum. Variation in ALT level, detailed kinetics of viral markers titer, and HBV DNA load were investigated during pregnancy. More importantly, ALT flare after delivery and efficacy of extended antiviral therapy, as well as the associated factors, were addressed.
Methods
Subjects and treatment. From March 2010 to May 2014, pregnant women from six hospitals in Shaanxi Province, China, were screened for eligibility to enroll in this study according to the following inclusion criteria: serum HBsAg(+) for more than 6 months, HBeAg(+), HBV DNA load > 10 6 IU/mL, and fetal gestational age less than 24 weeks; the exclusion criteria were coinfection with other viruses, diagnosis of cirrhosis, concurrent treatment with steroids, immune modulators or cytotoxic drugs, evidence of fetal deformity diagnosed by four-dimensional color Doppler ultrasound examination, or HBV infection of the biological father of the infant. After discussing the benefits and risks of telbivudine therapy during pregnancy, pregnant women signed the written informed consent forms, which were approved by the ethics committee of the First Affiliated Hospital of Xi'an Jiaotong University (number 2010-Lunshenkezi-No. 13).
The pregnant women received telbivudine (Novartis, Basel, Switzerland) at week 24 or 28 of gestation. According to the patients' condition and personal willingness and avoiding potential LdT resistance, some mothers switched to entecavir, and others ceased antiviral treatment at postpartum week (PPW) 12. Obstetric examination was conducted at each prepartum clinic visit, and details of delivery were recorded. Tests for HBV serum marker titer, ALT level, HBV DNA load, and creatine kinase (CK) were performed every 4 weeks prior to delivery and at PPWs 4, 12, 24, and 52. All infants received the following combined immunoprophylaxis schedule: hepatitis B immunoglobulin (200 IU; Hualan Biological Engineering Inc., Henan, China) and the first dose of hepatitis B vaccine (Shenzhen Kangtai Biological Products Co. Ltd., Guangdong, China) within 12 h postpartum, followed by an additional recombinant HBV vaccine dose at ages 1 and 6 months. The infants were followed up at ages 28 and 52 weeks. Serum was separated for HBV DNA load tests and measurement of HBV serum marker titer. The height, weight, and head circumference of each infant were also measured. Figure 1 presents a flow chart of the participant disposition in the current study. Vertical transmission of HBV was determined by HBsAg and HBV DNA testing from infant peripheral blood at 28 weeks of age.
Laboratory methods. Titers for HBsAg, anti-HBs, HBeAg, and anti-HBe were quantified with ARCHITECT assays (Abbott Laboratories, Chicago, IL, USA). The serum HBV DNA load was measured by real-time quantitative fluorescence polymerase chain reaction (Zhongshan University Da An Gene Co. Ltd., Guangzhou, China) with detection range of 1.0 × 10 2 to 1.0 × 10 9 IU/mL. Liver function and CK tests were performed with an automated bioanalyzer (Olympus AU5400, Mishama, Japan).
Statistical analysis. Data were analyzed statistically with SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Descriptive analysis was conducted. The χ 2 test or Fisher's exact analysis was used for comparison between two groups. The Shapiro-Wilk test and Levene statistic were used to evaluate the normality and homogeneity of the variance, respectively. According to the situation, the t-test or Mann-Whitney U-test was used to evaluate differences between two groups. Mixed ANOVA was used to compare trends and changes between two groups. Clinical correlates were assessed with multivariate analysis using the enter method of logistic regression. The significance level was set at P < 0.05.
Results
Baseline characteristics. Between March 2010 and May 2014, 268 mothers were enrolled. Of these, six subjects withdrew consent prior to the baseline visit, and 21 subjects were lost to follow-up because of changes of hospital or contact information. Therefore, 241 mothers were included in the final analysis. Table 1 presents the baseline characteristics of the mothers and growing information of the infants; although 10 mothers had a history of antiviral therapy before pregnancy, they did not have lamivudine M204I/V mutations at baseline. No significant difference was noted with respect to weight, height, or Apgar score in the newborns. Compared with the up-to-date growth reference values generated from the fourth National Survey on the Physical Growth and Development of Children in the Nine Cities of China, 23 no differences were observed in infant weight, and length at ages 7 and 12 months (Table 1) .
Elevated alanine aminotransferase during pregnancy. In this study, 160 mothers (66.4%) had a normal ALT level (upper limits of normal (ULN) = 40 U/L) throughout pregnancy, and 81 mothers (33.6%) showed elevated ALT level during pregnancy. The median time of onset of prepartum ALT elevation was 20 weeks of gestation (range: 12-39 weeks), and the median peak ALT during flare was 39.6 U/L (range: 7.0-393.5 U/L). ALT elevation was mild to moderate in a majority of the 81 mothers, and the onset time was mainly before the third trimester (Fig. 2a) .
Compared with baseline and in accordance with the literature, 6 ,24 telbivudine treatment significantly reduced the HBV DNA level in all mothers (5.68 ± 2.01, range: 1.33-8.95 Log 10 IU/mL), and consequently, 47.7% pregnant women (115/241) had an undetectable serum HBV DNA load prior to delivery (Fig. 2b) . With the viral level notably decreased, it was not surprising that the ALT level was normalized in 85.2% (69/81) of those expectant mothers before delivery (Fig. 2a) . When further comparing the dynamic changes of viral titer from mothers with normal ALT levels during pregnancy, a statistically rapid decline was displayed in the 81 mothers with ALT elevation (F = 12.010, P = 0.001; Fig. 2c ). The values are expressed as the median (range) except for "previous use of antiviral, mothers with elevated ALT level, Apgar score of 10," which are expressed as n (%). ALT, alanine aminotransferase; HBV, hepatitis B virus. Postpartum flare after telbivudine withdrawal. As mentioned earlier, 143 mothers (59.3%) ceased telbivudine treatment at PPW 12. Hepatitis flare can be induced by the withdrawal of antiviral treatment. 26, 27 During follow-up, 11.9% (17/143) of these subjects showed mild-to-moderate ALT flare after telbivudine is discontinued (ALT range: 61.2-234.0 U/L), which indicated that it is safe for the majority of mothers to stop telbivudine therapy after delivery. However, it is noteworthy that 25.0% (10/40) of women with elevated ALT level during pregnancy displayed postpartum flare after telbivudine withdrawal, which was much higher than the overall rate (25.0% vs 11.9%; χ 2 = 4.273, P = 0.039). For this special population, immediate withdrawal of antiviral therapy should be prudent. To further analyze the risk factors for postpartum flare after telbivudine withdrawal, mothers were categorized into groups. Of the 143 who ceased telbivudine treatment at PPW 12, 40 with elevated ALT during pregnancy were categorized as group 1, and the other 103 with normal ALT levels throughout pregnancy were assigned to group 2 (Sup. 1. Subgroup of the 241 mothers followed up for 52 weeks postpartum). Among the 98 mothers who chose to continue antiviral treatment after PPW 12, 46 had elevated ALT values before delivery (group 3), and the other 57 women with normal ALT were assigned to group 4. As shown in Table 2 , there were no significant differences between the four groups in the baseline virological characteristics of HBV DNA load, as well as titers of HBsAg and HBeAg.
Comparing group 1 with group 2, a statistically significant difference in the rate of ALT flare after telbivudine withdrawal was obtained (25.0% vs 6.8%; χ 2 = 9.115, P = 0.003; Fig. 3a) ; group 1 showed much higher peak ALT levels (109.3 vs 64.7 U/L; t = 2.715, P = 0.024; Fig. 3b) .
Furthermore, multivariate analysis was performed for mothers who stopped telbivudine therapy at PPW 12. Only elevation of ALT during pregnancy closely correlated with the development of a postpartum flare after telbivudine withdrawal (odds ratio = 7.553; Table 3 ).
Of the 81 women with elevated ALT level during pregnancy, when compared with the mothers who ceased telbivudine at PPW 12 (group 1), less ALT flare was observed in those that continued antiviral therapy (group 3) (7.3% [3/41] vs 25.0% [10/40] , χ 2 = 4.699, P = 0.030; Fig. 3a) . Additionally, the median peak ALT value was slightly lower in group 3 (67.0 U/L) than in group 1 (98.0, 70.0-234.0 U/L) (Fig. 3b) . Thus, extended antiviral therapy needs further investigation.
Extending antiviral treatment to the postpartum period. In our survey, 98 mothers opted for continued antiviral therapy after PPW 12 and switched to entecavir treatment. At the follow-up of PPWs 24 and 52, all mothers had no virologic breakthrough and hepatic flare.
Moreover, serological response was estimated at PPW 52 in the mothers; none obtained HBeAg seroconversion in the mothers who ceased telbivudine at PPW 12 (Fig. 3c, groups 1 and 2) . Compared with the women with normal ALT levels during pregnancy (group 4), those with elevated ALT (group 3) showed a higher HBeAg seroconversion rate (36.6% vs 8.8%; χ 2 = 11.852, P = 0.001; Fig. 3c ). HBsAg loss did not occur during the followup; however, HBsAg titer in group 3 decreased gradually, whereas the titer in group 4 did not show the downward trend (Fig. 3d) . The decline of HBsAg titer was 0.85 ± 0.36 Log 10 IU/mL in group 3 versus 0.51 ± 0.37 Log 10 IU/mL in group 4 (Z = -3.468, P = 0.001) from week 24 of gestation to PPW 52.
Efficacy and safety of telbivudine to prevent mother-to-infant transmission. All 241 infants born to HBsAg(+) mothers in the study received combined immunoprophylaxis within 12 h of birth, completed all vaccinations according to the protocol, and were followed up at ages 28 and 52 weeks. Of the infants followed for at least 28 weeks, only one (0.41%) was seropositive for HBsAg, HBeAg, and HBV DNA; all the other infants were negative for serum HBsAg and HBV DNA. The mother of the infected infant regularly took telbivudine from 28 weeks of gestation to PPW 12. Her HBV DNA load, HBsAg, and HBeAg titer at delivery were 3.94 Log 10 IU/mL, 4.66 Log 10 IU/mL, and 1087.452 s/co, respectively. She had cesarean delivery owing to oligoamnios, and the fetus had mild distress, while there was no threatened abortion, prolonged labor, postpartum hemorrhage, or common complications of gestation such as gestational diabetes mellitus, gestational hypertension, or anemia. The infant underwent combined immunoprophylaxis within 2 h postpartum and had normal development and no congenital deformities during the follow-up visit. Hepatic flare and effect of antivirus J Liu et al.
Telbivudine treatment was generally tolerated well by the pregnant women and their infants. Six adverse events were noted, namely fatigue, diarrhea, nausea, rash, insomnia, and elevated CK, while the incidence rate was comparable with that in chronic HBV-infected population. Additionally, no severe maternal adverse events were observed.
Discussion
In the current multicenter observational study, we investigated pregnancies that received LdT intervention for mother-to-infant transmission and monitored dynamic changes of liver inflammation and HBV DNA load. According to our knowledge, this is the largest detailed real-life survey from northwestern China; 241 mother-infant pairs were enrolled and had as long as 52 weeks of postpartum follow-up. Our results enhance the information about ALT flare during pregnancy and postpartum, as well as the relatively longtime outcome of mothers and infants, which would provide clinical support for standard guidelines for HBsAg(+) mothers. Owing to unique physiological and immune-mediated changes induced by pregnancy, a various course of chronic hepatitis B has been reported, 10, 11, 25 and ALT elevation has been mitigated even in chronically HBV-infected pregnant women with hepatic flare. 11, 24 In the current study, ALT level was elevated in 33.6% of women during pregnancy, increases were mainly mild-median, and the peak level was 93.0 U/L. Considering the systematic changes during pregnancy, mild ALT elevation may represent hepatic flare. LdT administration resulted in HBV DNA inhibition and hepatic flare deceleration. 20 In this study, a significant decrease in HBV DNA level was obtained (5.68 ± 2.01 Log 10 IU/mL), and the elevated ALT was normalized in 85.2% of mothers prior to delivery, which is consistent with previous results. 6, 7, 21 When compared with HBV DNA inhibition in the women with normal ALT levels, a substantial decrease was observed in those with elevated ALT (P = 0.001). Interestingly, the observed decrease in women with elevated ALT was comparable with that in the chronic HBVinfected population with hepatic flare (5.99 vs 6.1 Log 10 IU/mL, data not shown), 28 which also implies that mild ALT elevation during pregnancy may indicate inflammatory activity.
When maternal immunity is restored after giving birth, the pregnancy-associated changes described earlier generally reverse fairly rapidly, which may account for postpartum hepatic flare in pregnant women with HBV infection. 14, 15 Studies have shown that postpartum flare occurs in 25-44.7% of pregnant women and mainly happens during the first 3 months postpartum. 14, 15, 24, 25 Consistent with previous reports, we found that postpartum ALT flare mainly occurred within 12 weeks after delivery, and the incidence was 34.4%.
Withdrawal of antiviral treatment is another risk factor of hepatic flare; 26, 27 however, the risk of postpartum flare after antiviral therapy cessation in women with chronic HBV infection has not been well established. In this study, a total of 143 mothers stopped LdT treatment at PPW 12; only 11.9% of subjects showed mild-to-moderate ALT flare after discontinuing LdT therapy. This indicated that it is safe for most mothers to cease LdT therapy after delivery. Nevertheless, a significantly higher postpartum flare rate (25.0% vs 11.9%; P = 0.039) was noted for the women with elevated ALT during pregnancy, when comparing with those with normal ALT. More importantly, multivariate analysis of data for the mothers who stopped LdT therapy at PPW 12 showed that only elevation of ALT during pregnancy was closely associated with the development of postpartum flare after LdT withdrawal. Therefore, it is safe for the majority of the mothers to withdraw LdT after delivery, whereas antiviral withdrawal should be prudential for women with elevated ALT during pregnancy.
Nucleos(t)ide analog administration for patients in the immunoreactive HBeAg-positive phase can achieve virological remission, ALT normalization, and HBeAg seroconversion. In China, the majority of HBsAg(+) women of childbearing age obtain HBV infection owing to vertical transmission, who progress untoward outcomes faster after quite a long duration of immune tolerance. 1 Studies have manifested that patients with HBeAg seroconversion before age 30 years have the best outcomes and have an extremely low risk of disease progression. 29 ALT elevation during pregnancy represents hepatic flare, so it may be an valuable opportunity of treatment for those special population. In the current study, the benefit of extended antiviral treatment after delivery had been evaluated; a higher HBeAg seroconversion rate and a more significant decrease in HBsAg titer had been observed in mothers with elevated ALT during pregnancy, which is comparable with those in chronic HBV-infected patients, while the treatment duration, optimal strategy, long-term prognosis, and benefit-cost ratio remain to be studied.
Conclusion
It is safe for the majority of the mothers to withdraw LdT after delivery, while the women with elevated ALT during pregnancy had a higher risk for ALT flare after LdT withdrawal, and close monitoring is essential; extended administration of antiviral treatment for those women may lower the risk of postpartum flare and enhance HBeAg seroconversion and decrease HBsAg titer. It is necessary to tailor the intervention for each individual mother.
